Stock Scorecard



Stock Summary for Capricor Therapeutics Inc (CAPR) - $7.30 as of 5/13/2025 8:20:59 PM EST

Total Score

9 out of 30

Safety Score

38 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for CAPR

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for CAPR

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for CAPR

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for CAPR

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for CAPR (38 out of 100)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 3
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 4
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for CAPR

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR - Capricor Therapeutics ( NASDAQ:CAPR ) 5/9/2025 2:53:00 PM
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation - Virtus LifeSci Biotech Clinical Trials ETF ( ARCA:BBC ) , Capricor Therapeutics ( NASDAQ:CAPR ) 5/7/2025 1:56:00 PM
Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13 5/6/2025 1:15:00 PM
uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday - Avis Budget Gr ( NASDAQ:CAR ) , Capricor Therapeutics ( NASDAQ:CAPR ) 4/17/2025 2:30:00 PM
Robinhood, Couchbase And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Arhaus ( NASDAQ:ARHS ) 3/31/2025 12:06:00 PM
Check Out What Whales Are Doing With CAPR - Capricor Therapeutics ( NASDAQ:CAPR ) 3/27/2025 5:18:00 PM
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday - China Liberal Education ( NASDAQ:CLEU ) , Capricor Therapeutics ( NASDAQ:CAPR ) 3/20/2025 2:43:00 PM
Capricor Therapeutics ( CAPR ) Reports Q4 Loss, Tops Revenue Estimates 3/19/2025 9:15:00 PM
Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update 3/19/2025 8:05:00 PM
Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy 3/17/2025 1:25:00 PM

Financial Details for CAPR

Company Overview

Ticker CAPR
Company Name Capricor Therapeutics Inc
Country USA
Description Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapies for the treatment and prevention of a broad spectrum of diseases. The company is headquartered in Beverly Hills, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 7.30
Price 4 Years Ago 2.93
Last Day Price Updated 5/13/2025 8:20:59 PM EST
Last Day Volume 4,617,118
Average Daily Volume 2,110,518
52-Week High 23.40
52-Week Low 3.52
Last Price to 52 Week Low 107.39%

Valuation Measures

Trailing PE N/A
Industry PE 29.04
Sector PE 49.22
5-Year Average PE -4.75
Free Cash Flow Ratio 29.20
Industry Free Cash Flow Ratio 19.04
Sector Free Cash Flow Ratio 31.82
Current Ratio Most Recent Quarter 7.77
Total Cash Per Share 0.25
Book Value Per Share Most Recent Quarter 3.19
Price to Book Ratio 1.99
Industry Price to Book Ratio 38.21
Sector Price to Book Ratio 30.58
Price to Sales Ratio Twelve Trailing Months 14.58
Industry Price to Sales Ratio Twelve Trailing Months 93.50
Sector Price to Sales Ratio Twelve Trailing Months 25.54
Analyst Buy Ratings 4
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 45,676,900
Market Capitalization 333,441,370
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -81.57%
Reported EPS 12 Trailing Months -1.15
Reported EPS Past Year 0.00
Reported EPS Prior Year -1.20
Net Income Twelve Trailing Months -40,467,186
Net Income Past Year -40,467,186
Net Income Prior Year -22,287,542
Quarterly Revenue Growth YOY -7.90%
5-Year Revenue Growth 85.83%
Operating Margin Twelve Trailing Months -69.20%

Balance Sheet

Total Cash Most Recent Quarter 11,286,996
Total Cash Past Year 11,286,996
Total Cash Prior Year 14,694,857
Net Cash Position Most Recent Quarter 7,910,737
Net Cash Position Past Year 7,910,737
Long Term Debt Past Year 3,376,259
Long Term Debt Prior Year 3,376,259
Total Debt Most Recent Quarter 3,376,259
Equity to Debt Ratio Past Year 0.98
Equity to Debt Ratio Most Recent Quarter 0.98
Total Stockholder Equity Past Year 145,462,336
Total Stockholder Equity Prior Year 22,601,467
Total Stockholder Equity Most Recent Quarter 145,462,336

Free Cash Flow

Free Cash Flow Twelve Trailing Months -41,534,717
Free Cash Flow Per Share Twelve Trailing Months -0.91
Free Cash Flow Past Year -41,534,717
Free Cash Flow Prior Year -27,644,078

Options

Put/Call Ratio 0.09
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -1.01
MACD Signal -0.38
20-Day Bollinger Lower Band 7.16
20-Day Bollinger Middle Band 12.56
20-Day Bollinger Upper Band 17.95
Beta 0.86
RSI 28.83
50-Day SMA 11.20
150-Day SMA 6.88
200-Day SMA 6.12

System

Modified 5/13/2025 7:57:10 PM EST